High risk, relapsed Neuroblastomas of the bone or bone marrow
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB15965 | Naxitamab | A GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow. |
| Drug | Drug Name | Target | Type |
|---|---|---|---|
| DB15965 | Naxitamab | GD2 disialoganglioside | target |
| Drug | Drug Name | Phase | Status | Count |
|---|